Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions

Fenebrutinib is a CYP3A substrate and time‐dependent inhibitor, as well as a BCRP and OATP1B transporter inhibitor in vitro. Physiologically‐based pharmacokinetic (PBPK) modeling strategies with the ultimate goal of understanding complex drug‐drug interactions (DDIs) and proposing doses for untested...

Full description

Bibliographic Details
Main Authors: Yuan Chen, Fang Ma, Nicholas S. Jones, Kenta Yoshida, Po‐Chang Chiang, Matthew R. Durk, Matthew R. Wright, Jin Yan Jin, Leslie W. Chinn
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12515

Internet

https://doi.org/10.1002/psp4.12515

Similar Items